Cue Biopharma is trading at $15.01, down 6.65%, with no confirmed company-specific catalyst identified for the October 20 pre-market decline. - The biotech sector is also under pressure: provided context reports XBI down 3.65% pre-market, which may be contributing. - September 20 CUE-221 Phase 2 results are earlier news, not a clear explanation for this move; coverage reported the stock had fallen sharply after the trial win.